Total Payments
$4,137
2024 Payments
$982.59
Companies
31
Transactions
224
Medicare Patients
11,421
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$4,135 (99.9%)
Education$2.31 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,135 | 223 | 99.9% |
| Education | $2.31 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $605.82 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $548.01 | 38 | $0 (2024) |
| PFIZER INC. | $509.73 | 28 | $0 (2024) |
| Amgen Inc. | $475.38 | 27 | $0 (2024) |
| Boston Scientific Corporation | $311.23 | 11 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $268.30 | 15 | $0 (2023) |
| Lundbeck LLC | $154.81 | 3 | $0 (2019) |
| Impulse Dynamics (USA) Inc. | $146.36 | 6 | $0 (2024) |
| Abbott Laboratories | $123.84 | 7 | $0 (2023) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $116.47 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $982.59 | 52 | PFIZER INC. ($214.01) |
| 2023 | $803.20 | 39 | Amgen Inc. ($134.04) |
| 2022 | $720.72 | 46 | Novartis Pharmaceuticals Corporation ($189.71) |
| 2021 | $193.12 | 11 | Janssen Pharmaceuticals, Inc ($70.09) |
| 2020 | $183.87 | 11 | Janssen Pharmaceuticals, Inc ($75.70) |
| 2019 | $599.47 | 29 | Lundbeck LLC ($154.81) |
| 2018 | $320.03 | 18 | Janssen Pharmaceuticals, Inc ($114.92) |
| 2017 | $334.17 | 18 | Gilead Sciences Inc ($66.20) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/27/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Cardiology | ||||||
| 11/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Not Applicable | ||||||
| 11/12/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $22.80 | General |
| Category: Cardiovascular Device | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.69 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 10/24/2024 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: WATCHMAN_IC | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.39 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.45 | General |
| Category: Cardiovascular | ||||||
| 09/25/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Not Applicable | ||||||
| 09/16/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Cardiology | ||||||
| 09/10/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $11.03 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/07/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/23/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/22/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.58 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,820 | 4,657 | $680,593 | $273,747 |
| 2022 | 12 | 2,806 | 4,875 | $679,000 | $267,345 |
| 2021 | 14 | 2,793 | 4,883 | $691,123 | $282,206 |
| 2020 | 20 | 3,002 | 5,344 | $805,403 | $298,728 |
Total Patients
11,421
Total Services
19,759
Medicare Billing
$1.1M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 536 | 774 | $164,862 | $71,250 | 43.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 275 | 1,118 | $163,228 | $69,842 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 792 | 1,094 | $158,630 | $69,664 | 43.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 180 | 213 | $58,575 | $21,894 | 37.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $18,639 | $6,731 | 36.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 514 | 576 | $27,072 | $5,867 | 21.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 79 | 88 | $17,864 | $5,775 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 71 | $15,123 | $5,382 | 35.6% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 95 | 242 | $16,698 | $4,631 | 27.7% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 94 | 242 | $15,488 | $3,453 | 22.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 66 | 88 | $8,456 | $3,345 | 39.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $7,704 | $2,754 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 15 | 15 | $4,905 | $1,531 | 31.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 23 | 29 | $2,262 | $1,138 | 50.3% |
| 93279 | Programming of single lead pacemaker system | Office | 2023 | 11 | 14 | $1,088 | $489.24 | 45.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 279 | 1,289 | $188,194 | $72,728 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 816 | 1,115 | $161,675 | $69,239 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 513 | 718 | $152,934 | $66,516 | 43.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 233 | 300 | $60,900 | $23,808 | 39.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 558 | 683 | $32,101 | $6,910 | 21.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $14,715 | $5,794 | 39.4% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 88 | 242 | $16,698 | $4,712 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 43 | 58 | $12,354 | $4,547 | 36.8% |
| 93280 | Programming of dual lead pacemaker system | Office | 2022 | 76 | 109 | $9,329 | $3,879 | 41.6% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2022 | 88 | 243 | $15,552 | $3,697 | 23.8% |
About Maged Haikal
Maged Haikal is a Cardiovascular Disease healthcare provider based in Chesterfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306803309.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Maged Haikal has received a total of $4,137 in payments from pharmaceutical and medical device companies, with $982.59 received in 2024. These payments were reported across 224 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($4,135).
As a Medicare-enrolled provider, Haikal has provided services to 11,421 Medicare beneficiaries, totaling 19,759 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Chesterfield, MO
- Active Since 04/26/2006
- Last Updated 12/14/2017
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1306803309
Products in Payments
- XARELTO (Drug) $605.82
- ENTRESTO (Drug) $382.22
- ELIQUIS (Drug) $320.44
- Repatha (Biological) $317.55
- WATCHMAN (Device) $255.95
- JARDIANCE (Drug) $196.14
- LEQVIO (Drug) $165.79
- Corlanor (Drug) $157.83
- NORTHERA (Drug) $154.81
- VYNDAQEL (Drug) $153.93
- LifeVest (Device) $116.47
- VERQUVO (Drug) $99.04
- MULTAQ (Drug) $92.64
- OPTIMIZER (Device) $91.97
- Arcalyst (Drug) $87.87
- Barostim Neo System (Device) $85.47
- PRADAXA (Drug) $72.16
- BYSTOLIC (Drug) $71.87
- CAMZYOS (Drug) $70.52
- WATCHMAN Access System (Device) $55.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chesterfield
Dr. Glenn Davison, M.d, M.D
Cardiovascular Disease — Payments: $175,166
Cardiovascular Disease $175,166
James Ellison, Md, MD
Cardiovascular Disease — Payments: $136,879
Cardiovascular Disease $136,879
Dr. Keith Mankowitz, Md, MD
Cardiovascular Disease — Payments: $73,624
Cardiovascular Disease $73,624
Dr. Jonas Cooper, Md, MD
Cardiovascular Disease — Payments: $45,608
Cardiovascular Disease $45,608
Dr. Craig Reiss, Md, MD
Cardiovascular Disease — Payments: $7,942
Cardiovascular Disease $7,942
Salman Waheed, M.d., M.p.h, M.D., M.P.H
Cardiovascular Disease — Payments: $3,364
Cardiovascular Disease $3,364